Kodiak Sciences Inc. (KOD)

US — Healthcare Sector

Peers: RVPHW EYEN CGTX RNAZ ASMB TIL NLTX SPRO CTMX CKPT MBIO RVPH FBIOP ICPT MDGL SRPT MRTX BMEA STOK AKRO FIXX GOSS

Automate Your Wheel Strategy on KOD

With Tiblio's Option Bot, you can configure your own wheel strategy including KOD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol KOD
Rev/Share 0.0
Book/Share 2.0635
PB 1.6477
Debt/Equity 0.6214
CurrentRatio 4.6212
ROIC -0.6833

MktCap 179395900.0
FreeCF/Share -2.0365
PFCF -1.6701
PE -1.3467
Debt/Assets 0.227
DivYield 0
ROE -0.8083

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 3
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Upgrade	KOD	Jefferies	Hold	Buy	--	$20	Dec. 9, 2024
Initiation	KOD	H.C. Wainwright	--	Neutral	--	$3	Sept. 5, 2024

News

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

KOD
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral

PALO ALTO, Calif. , May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.

image for news Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative

KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.

image for news Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

KOD
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Negative

KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.

image for news Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

KOD
Published: February 23, 2025 by: Seeking Alpha
Sentiment: Positive

Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.

image for news Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

About Kodiak Sciences Inc. (KOD)

IPO Date 2018-10-04
Website https://kodiak.com
Industry Biotechnology
CEO Dr. Victor Perlroth M.D.
Employees 109

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.